Combined XXXX and rituximab for @entity1893 and @entity1072 .

@entity1 @entity137 @entity1071 @entity1072 @entity3118 @entity1893 @entity2021
As both @entity3118 and rituximab are active against @entity1071 , we have studied the combination of @entity3118 and rituximab in @entity1 with @entity1893 and @entity1072 ( @entity1072 ) in phase I/II fashion. Of 33 @entity1 enrolled, 21(63.6%) had @entity1893 and 12 (36.4%) had @entity1072 . They received @entity3118 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three @entity1 were removed from the study because of rituximab-associated @entity2021 and four because of prolonged @entity137 . @entity137 and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable @entity1 , responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding @entity1 not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated @entity1 , all responded and 46.2% had a complete response. Of 16 previously treated @entity1 , 68.5% responded and 25% had a complete response. The combination of @entity3118 and rituximab has major activity and acceptable @entity137 in @entity1 with @entity1893 and @entity1072 .
